Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience

References

• Duarte RF, Labopin M, Bader P, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525–1552. doi: 10.1038/s41409-019-0516-2
   PubMed Web of Science ®Google Scholar
• Ferrara J, Levine J, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. doi: 10.1016/S0140-6736(09)60237-3
   PubMed Web of Science ®Google Scholar
• Kilgour JM, Wali G, Gibbons E, et al. Systematic review of patient-reported outcome measures in graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):e113–e127. doi: 10.1016/j.bbmt.2020.01.022
   PubMed Web of Science ®Google Scholar
• Szydlo R, Goldman J, Klein J, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–1777. doi: 10.1200/JCO.1997.15.5.1767
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell P, Symons H, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi: 10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore C, et al. T-Cell–replete HLA-Haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-Matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310–1316. doi: 10.1200/JCO.2012.44.3523
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24. doi: 10.1038/nrclinonc.2015.128
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez J, Salazar-Cavazos L, Aguilar-Calderón P, et al. Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country. Bone Marrow Transplant. 2018;54(6):828–838. doi: 10.1038/s41409-018-0338-7
   PubMed Web of Science ®Google Scholar
• Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387–9393. doi: 10.1200/JCO.2005.02.0057
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez J, Hernández-Coronado M, Picón-Galindo E, et al. Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning. Leuk Lymphoma. 2021;62(7):1619–1628. doi: 10.1080/10428194.2021.1876870
   PubMed Web of Science ®Google Scholar
• Colunga-Pedraza P, Gómez-De León A, Rodríguez-Roque C, et al. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is safe and feasible. Transplant Cell Ther. 2021;27(3):.e259.1–.e259.6. doi: 10.1016/j.jtct.2020.12.006
   Google Scholar
• Jagasia M, Greinix H, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18(4):295–304. doi: 10.1097/00007890-197410000-00001
   PubMed Web of Science ®Google Scholar
• Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant. 2015;21(6):984–999. doi: 10.1016/j.bbmt.2015.02.025
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Meléndez-Flores JD, Ramos-Dávila EM, et al. Infection-related mortality after HLA-identical and haploidentical hematopoietic cell transplantation using reduced-intensity conditioning in an outpatient setting. Clin Transplant. 2023;37(6):e14972. doi: 10.1111/ctr.14972
   PubMed Web of Science ®Google Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. N Engl J Med. 2014;371(4):339–348. doi: 10.1056/NEJMsa1311707
   PubMed Web of Science ®Google Scholar
• Shouval R, Fein J, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a european society for blood and marrow transplantation registry retrospective analysis. Lancet Haematol. 2019;6(11):e573–e584. doi: 10.1016/S2352-3026(19)30158-9
   PubMed Web of Science ®Google Scholar
• How J, Slade M, Vu K, et al. T cell–replete peripheral Blood Haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(4):648–653. doi: 10.1016/j.bbmt.2017.01.068
   PubMed Web of Science ®Google Scholar
• Nagler A, Labopin M, Houhou M, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the acute leukemia working party of the European Society for Blood and marrow transplantation. J Hematol Oncol. 2021;14(1):53.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Milton D, Poon L, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen–matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975–1981. doi: 10.1016/j.bbmt.2014.08.013
   PubMed Web of Science ®Google Scholar
• Krenger W, Ferrara J. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996;15(1):50–73. doi: 10.1007/BF02918284
   PubMed Web of Science ®Google Scholar
• Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19(16):3685–3691. doi: 10.1200/JCO.2001.19.16.3685
   PubMed Web of Science ®Google Scholar
• Castagna L, Crocchiolo R, Furst S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a Nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014;20(5):724–729. doi: 10.1016/j.bbmt.2014.02.001
   PubMed Web of Science ®Google Scholar
• Solh M, Baron J, Zhang X, et al. Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors. Biol Blood Marrow Transplant. 2020;26(11):2082–2088. doi: 10.1016/j.bbmt.2020.07.035
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132–e143. doi: 10.1016/S2352-3026(18)30221-7
   PubMed Web of Science ®Google Scholar
• Ciurea S, Zhang M, Bacigalupo A, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040. doi: 10.1182/blood-2015-04-639831
   PubMed Web of Science ®Google Scholar
• Nunes N, Kanakry C. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:10. doi: 10.3389/fimmu.2019.02668
   PubMed Web of Science ®Google Scholar
• Wachsmuth L, Patterson M, Eckhaus M, et al. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373. doi: 10.1172/JCI124218
   PubMed Web of Science ®Google Scholar
• Kanakry C, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211). doi: 10.1126/scitranslmed.3006960
   PubMed Web of Science ®Google Scholar
• Broers AEC, de Jong CN, Bakunina K, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6(11):3378–3385. doi: 10.1182/bloodadvances.2021005847
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Hamadani M, Wu J, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338–2348. doi: 10.1056/NEJMoa2215943
   PubMed Web of Science ®Google Scholar
• A randomized, multicenter, phase III trial of Tacrolimus/Methotrexate versus post-transplant Cyclophosphamide/Tacrolimus/Mycophenolate mofetil in non-myeloablative/Reduced intensity conditioning allogeneic peripheral blood stem cell transplantation (PROGRESS III). (2020). Retrieved from: https://clinicaltrials.gov/ProvidedDocs/41/NCT03959241/Prot_SAP_ICF_000.pdf. ( Identification No. NCT 03959241)
   Google Scholar
• Elmariah H, Naqvi SMH, Kim J, et al. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021;56(7):1683–1690. doi: 10.1038/s41409-021-01219-8
   PubMed Web of Science ®Google Scholar
• Danylesko I, Peczynski C, Labopin M, et al. Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: from the ALWP of the EBMT. Bone Marrow Transplant. 2022;57(8):1260–1268. doi: 10.1038/s41409-022-01695-6
   PubMed Web of Science ®Google Scholar
• Kasamon Y, Luznik L, Leffell M, et al. Nonmyeloablative HLA-Haploidentical Bone Marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482–489. doi: 10.1016/j.bbmt.2009.11.011
   PubMed Web of Science ®Google Scholar
• De León A, Mancias-Guerra C, Colunga-Pedraza P, et al. HLA-Matched related versus haploidentical peripheral blood stem cell transplantation in adults and children. Real world outcomes in Mexico. Biology Of Blood And Marrow Transplantation. 2019;25(3):S215. doi: 10.1016/j.bbmt.2018.12.294
   Web of Science ®Google Scholar
• Couriel D, Saliba R, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10(3):178–185. doi: 10.1016/j.bbmt.2003.10.006
   PubMed Web of Science ®Google Scholar
• Sugita J, Kagaya Y, Miyamoto T, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2018;54(3):432–441. doi: 10.1038/s41409-018-0279-1
   PubMed Web of Science ®Google Scholar
• Aoudjhane M, Labopin M, Gorin N, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19(12):2304–2312. doi: 10.1038/sj.leu.2403967
   PubMed Web of Science ®Google Scholar
• Holtan SG, Hamadani M, Wu J, et al. Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. Blood. 2022;140(Supplement 2):LBA–4. doi: 10.1182/blood-2022-171463
   Google Scholar
• Shlomchik W, Couzens M, Tang C, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–415. doi: 10.1126/science.285.5426.412
   PubMed Web of Science ®Google Scholar
• Saito A, Zahrieh D, Cutler C, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;40(3):209–217. doi: 10.1038/sj.bmt.1705733
   PubMed Web of Science ®Google Scholar
• Svahn B, Alvin O, Ringdén O, et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(2):147–153. doi: 10.1097/01.tp.0000226171.43943.d3
   PubMed Web of Science ®Google Scholar
• Subirà M, Sureda A, Ancín I, et al. Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure. Bone Marrow Transplant. 2003;32(9):869–872. doi: 10.1038/sj.bmt.1704254
   PubMed Web of Science ®Google Scholar
• Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplant. 2006;37(3):289–296. doi: 10.1038/sj.bmt.1705247
   PubMed Web of Science ®Google Scholar
• Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan marrow donor program. Br J Haematol. 2007;137(2):142–151. doi: 10.1111/j.1365-2141.2007.06543.x
   PubMed Web of Science ®Google Scholar
• Saccardi R, Tucunduva L, Ruggeri A, et al. Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for blood and marrow transplantation and NetCord retrospective analysis. Transfusion. 2016;56(8):2021–2029. doi: 10.1111/trf.13661
   PubMed Web of Science ®Google Scholar
• Pulsipher M, Langholz B, Wall D, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant. 2015;50(9):1173–1179. doi: 10.1038/bmt.2015.103
   PubMed Web of Science ®Google Scholar
• Boyiadzis M, Arora M, Klein J, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2014;21(9):2020–2028. doi: 10.1158/1078-0432.CCR-14-0586
   PubMed Web of Science ®Google Scholar
• Guru Murthy G, Hari P, Szabo A, et al. Outcomes of reduced-intensity conditioning allogeneic hematopoietic cell transplantation performed in the inpatient versus outpatient setting. Biology Blood Marrow Transplant. 2019;25(4):827–833. doi: 10.1016/j.bbmt.2018.12.069
   PubMed Web of Science ®Google Scholar
• Nycz B, Dominguez S, Friedman D, et al. Correction: evaluation of bloodstream infections, clostridium difficile infections, and gut microbiota in pediatric oncology patients. PloS One. 2018;13(5):e0197530. doi: 10.1371/journal.pone.0197530
   PubMed Web of Science ®Google Scholar
• Axt L, Naumann A, Toennies J, et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(11):1805–1814. doi: 10.1038/s41409-019-0544-y
   PubMed Web of Science ®Google Scholar
• Onishi Y, Mori T, Kako S, et al. Outcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2017;23(12):2137–2142. doi: 10.1016/j.bbmt.2017.08.020
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Hara M, Tachibana T, et al. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol. 2019;186(1):86–90. doi: 10.1111/bjh.15898
   PubMed Web of Science ®Google Scholar
• Canals C, Muñiz-Díaz E, Martínez C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion. 2004;44(11):1603–1611. doi: 10.1111/j.1537-2995.2004.04106.x
   PubMed Web of Science ®Google Scholar
• Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study. Bone Marrow Transplant. 2007;41(4):399–405. doi: 10.1038/sj.bmt.1705913
   PubMed Web of Science ®Google Scholar